Discounted Cash Flow
Ideaya Biosciences, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2011 | $23.8m | $-3.1m | $1.9m | -13.2% | $-0.24 |
| 2017 | — | $-11.9m (-278.2%) | $-12.3m (-752.6%) | — | — |
| 2018 | $2.1m | $-34.3m (-189.5%) | $-28.2m (-129.6%) | -1658.4% | — |
| 2019 | $2.3m (10.9%) | $-42.0m (-22.2%) | $-39.3m (-39.3%) | -1828.2% (-10.2%) | — |
| 2020 | $19.5m (751.0%) | $-34.5m (17.8%) | $54.9m (239.8%) | -176.6% (90.3%) | — |
| 2021 | $27.9m (43.0%) | $-49.8m (-44.3%) | $-55.9m (-201.7%) | -178.1% (-0.9%) | — |
| 2022 | $50.9m (82.3%) | $-58.7m (-17.9%) | $-87.6m (-56.7%) | -115.2% (35.3%) | $-1.42 |
| 2023 | $23.4m (-54.1%) | $-113.0m (-92.6%) | $-115.4m (-31.8%) | -483.0% (-319.4%) | $-1.96 (-38.0%) |
| 2024 | $7.0m (-70.1%) | $-274.5m (-143.0%) | $-249.1m (-115.9%) | -3921.1% (-711.7%) | $-3.36 (-71.4%) |
| 2025 | $218.7m (3024.4%) | $-113.7m (58.6%) | $-72.2m (71.0%) | -52.0% (98.7%) | $-1.28 (61.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.